Status:

UNKNOWN

Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer

Lead Sponsor:

Sun Yat-sen University

Collaborating Sponsors:

Affiliated Cancer Hospital of Shantou University Medical College

Shanghai Chest Hospital

Conditions:

Squamous Cell Esophageal Carcinoma

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

The primary objective is to compare neo-adjuvant chemoradiotherapy followed by surgery versus surgery, in terms of the overall survival time (OS) in patients with Stage IIB or III squamous cell esopha...

Detailed Description

Esophageal cancer (EC) is the eighth most common cancers in the world, with more than 480,000 new cases and 400,000 deaths occurred annually worldwide. In China, every year, no matter new cases or dea...

Eligibility Criteria

Inclusion

  • Histologic diagnosis of squamous cell thoracic esophageal carcinoma of Stage IIB or III, which is potentially resectable.
  • Patients must not have received any prior anticancer therapy.
  • More than 6 months of expected survival.
  • Age ranges from 18 to 70 years.
  • Absolute white blood cells count ≥4.0×109/L, neutrophil ≥1.5×109/L, platelets ≥100.0×109/L, hemoglobin ≥90g/L, and normal functions of liver and kidney.
  • Karnofsky performance status (KPS) of 90 or more.
  • Signed informed consent document on file.

Exclusion

  • Patients are diagnosed or suspected to be allergic to cisplatin or vinorelbine.
  • Patients with concomitant hemorrhagic disease.
  • Pregnant or breast feeding.
  • Inability to use gastric conduit after esophagectomy because of a prior surgery.
  • Patients with concomitant peripheral neuropathy, whose CTC status is 2 or even more.
  • Have a prior malignancy other than esophageal carcinoma, carcinoma in situ of the cervix, nonmelanoma skin cancer or cured early stage of prostate cancer.

Key Trial Info

Start Date :

June 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2019

Estimated Enrollment :

430 Patients enrolled

Trial Details

Trial ID

NCT01216527

Start Date

June 1 2007

End Date

December 1 2019

Last Update

February 27 2017

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sun Yat-sen Uniersity Cancer Center

Guangzhou, Guangdong, China, 510060

2

Cancer Hospital of Shantou University Medical College

Shantou, Guangdong, China, 515000